卡巴他赛治疗伴有脑转移的去势抵抗性前列腺癌：3例病例报告
Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.
作者信息
De Placido Sabino, Rescigno Pasquale, Federico Piera, Buonerba Carlo, Bosso Davide, Puglia Livio, Izzo Michela, Policastro Tania, Di Lorenzo Giuseppe
机构信息
Pasquale Rescigno, Piera Federico, Carlo Buonerba, Davide Bosso, Livio Puglia, Michela Izzo, Tania Policastro, Sabino De Placido, Giuseppe Di Lorenzo, Genitourinary Cancer Section, Medical Oncology, Department of Clinical Medicine, Federico II University, Napoli 80140, Italy.
出版信息
World J Clin Cases. 2014 Jun 16;2(6):228-31. doi: 10.12998/wjcc.v2.i6.228.
Abstract
Prostate cancer is the most common non-cutaneous malignancy for men. The skeleton is the most common metastatic site but, following an improvement in survival, metastases in uncommon sites are being found more frequently in clinical practice, especially brain metastases. Despite the new drugs now available for metastatic castration resistant prostate cancer, no clinical evidence exists about their effectiveness on brain metastases. We describe the clinical history of 3 patients treated with cabazitaxel plus whole brain radiotherapy. These case reports demonstrate that cabazitaxel is highly active and well tolerated in brain metastases.
摘要
前列腺癌是男性最常见的非皮肤恶性肿瘤。骨骼是最常见的转移部位，但随着生存率的提高，在临床实践中，罕见部位的转移越来越常见，尤其是脑转移。尽管目前有新药可用于转移性去势抵抗性前列腺癌，但尚无关于其对脑转移有效性的临床证据。我们描述了3例接受卡巴他赛联合全脑放疗治疗患者的临床病史。这些病例报告表明，卡巴他赛在脑转移中具有高活性且耐受性良好。
相似文献
1
Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports.
World J Clin Cases. 2014 Jun 16;2(6):228-31. doi: 10.12998/wjcc.v2.i6.228.
2
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
3
Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.
Lancet Oncol. 2019 Oct;20(10):1432-1443. doi: 10.1016/S1470-2045(19)30408-5. Epub 2019 Sep 9.
4
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
5
An observational, multicentre study of cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (CAPRISTANA).
BJU Int. 2019 Mar;123(3):456-464. doi: 10.1111/bju.14509. Epub 2018 Sep 16.
6
Correlation between Automated Bone Scan Index Change after Cabazitaxel and Survival among Men with Castration-Resistant Prostate Cancer.
Urol Int. 2019;103(3):279-284. doi: 10.1159/000502655. Epub 2019 Aug 28.
7
Headache Caused by Brain Metastases of Castration-resistant Prostate Cancer during Cabazitaxel Therapy.
Keio J Med. 2017 Dec 25;66(4):65-71. doi: 10.2302/kjm.2016-0014-CR. Epub 2017 Apr 7.
8
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study.
Urol Oncol. 2017 Apr;35(4):149.e7-149.e13. doi: 10.1016/j.urolonc.2016.11.005. Epub 2017 Feb 1.
9
Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer.
Asia Pac J Clin Oncol. 2019 Dec;15(6):288-295. doi: 10.1111/ajco.13193. Epub 2019 Jul 16.
10
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
Ann Oncol. 2017 Jan 1;28(1):90-95. doi: 10.1093/annonc/mdw441.
引用本文的文献
1
Case Report: Abiraterone in brain metastases from prostate cancer.
Front Oncol. 2025 Apr 11;15:1555897. doi: 10.3389/fonc.2025.1555897. eCollection 2025.
2
The Clinical, Diagnostic, Therapeutic, and Prognostic Characteristics of Brain Metastases in Prostate Cancer: A Systematic Review.
Prostate Cancer. 2022 Nov 27;2022:5324600. doi: 10.1155/2022/5324600. eCollection 2022.
3
Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.
In Vivo. 2022 Jul-Aug;36(4):1841-1846. doi: 10.21873/invivo.12901.
4
Three cases of brain metastasis from castration-resistant prostate cancer.
Clin Case Rep. 2019 Dec 4;8(1):96-99. doi: 10.1002/ccr3.2587. eCollection 2020 Jan.
5
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Drugs. 2019 Mar;79(4):381-400. doi: 10.1007/s40265-019-1060-5.
6
Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review.
J Neurooncol. 2017 Jul;133(3):531-538. doi: 10.1007/s11060-017-2460-6. Epub 2017 May 25.
7
Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer.
Medicine (Baltimore). 2016 Jan;95(2):e2299. doi: 10.1097/MD.0000000000002299.
本文引用的文献
1
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.
Prostate. 2014 Feb;74(2):210-6. doi: 10.1002/pros.22742. Epub 2013 Oct 16.
2
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
Future Oncol. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39.
3
Cancer statistics, 2013.
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
4
Frequency of brain metastases from prostate cancer: an 18-year single-institution experience.
J Neurooncol. 2013 Jan;111(2):163-7. doi: 10.1007/s11060-012-0994-1. Epub 2012 Oct 25.
5
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc.
6
Use of palliative radiotherapy in brain and bone metastases (VARA II study).
Radiat Oncol. 2012 Aug 3;7:131. doi: 10.1186/1748-717X-7-131.
7
Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality.
Cancer. 2012 Jun 15;118(12):3062-70. doi: 10.1002/cncr.26392. Epub 2011 Oct 17.
8
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X.
9
Stereotactic radiosurgical treatment of parenchymal brain metastases from prostate adenocarcinoma.
Surg Neurol. 2008 Jun;69(6):641-6; discussion 646. doi: 10.1016/j.surneu.2007.05.035. Epub 2008 Feb 8.
10
Are abstracts presented at the EAU meeting followed by publication in peer-reviewed journals? A critical analysis.
Eur Urol. 2007 Mar;51(3):833-40; discussion 840. doi: 10.1016/j.eururo.2006.10.024. Epub 2006 Oct 25.
Zotero 插件